RxDoctor Payments Data

Jeffrey Kafer, MD

Internal Medicine · Roxboro, NCNPI 1609830389

Payments from drug & device makers

$7,613in general payments, 2019–2025

Across 460 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$817
  • AstraZeneca$679
  • Pfizer$495
  • AbbVie$492
  • E.r. Squibb & Sons, L.L.C.$390
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,613 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$225,302
Medicare patients
597
Services billed
4,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$141,078
OzempicSemaglutide89$100,770
FarxigaDapagliflozin Propanediol83$76,047
JardianceEmpagliflozin34$40,979
MounjaroTirzepatide35$35,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$32,832
XareltoRivaroxaban40$26,963
OxycontinOxycodone Hcl11$21,157
Tresiba Flextouch U-100Insulin Degludec40$14,058
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$13,185
Breo ElliptaFluticasone/Vilanterol15$7,916
JanuviaSitagliptin Phosphate11$7,848
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,603
Atorvastatin Calcium458$3,972
Pantoprazole Sodium332$3,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$495$141,078134 claims
Novo NordiskOzempic$1,440$100,77089 claims
AstraZenecaFarxiga$679$76,04783 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$375$46,35160 claims
Boehringer IngelheimJardiance$194$40,97934 claims
Lilly USA, LLCMounjaro, Humulin 70-30$817$37,66346 claims
Johnson & JohnsonXarelto$340$26,96340 claims
MerckJanuvia$167$7,84811 claims
Hikma Pharmaceuticals USAMitigare$21$2,31813 claims
Sanofi-aventis U.S. LLCLantus$128$2,31117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Roxboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →